Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ:MDWD)

20.73 +0.31 (+1.52%)
Streaming Delayed Price Updated: 10:33 AM EDT, Jun 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
Earnings Scheduled For May 17, 2022
Companies Reporting Before The Bell • On Holding (NYSE:ONON) is likely to report earnings for its first quarter. 
Via Benzinga
Preview: MediWound's Earnings
MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that MediWound will... 
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
MediWound: Q4 Earnings Insights
MediWound (NASDAQ:MDWD) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
MediWound Earnings Preview
MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
MediWound Posts Promising EscharEx Data For Chronic Wounds
MediWound Ltd (NASDAQ: MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers (VLUs). 
Via Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
Earnings Scheduled For March 17, 2022
Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ:IKNA) is... 
Via Benzinga
36 Stocks Moving In Thursday's Mid-Day Session
Gainers Indonesia Energy Corporation Limited (NASDAQ: INDO) shares jumped 46% to $21.13 after jumping around 35% on Wednesday. Eos Energy Enterprises, Inc. (NASDAQ: EOSE... 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers Indonesia Energy Corporation Limited (NASDAQ: INDO) shares climbed 39.3% to close at $20.20 on Thursday after jumping around 35% on Wednesday. DBV Technologies S.A. (... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! In preparation for another busy day of trading, we've put together a list of the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
MediWound Receives Additional $9M From BARDA For NexoBrid FDA Application Resubmission
The Biomedical Advanced Research and Development Authority (BARDA) will  
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
MediWound's EscharEx Mid-Stage Trial Meets Primary Goal In Venous Leg Ulcers
MediWound Ltd (NASDAQ: MDWD) has posted topline results from its U.S. Phase 2 study of EscharEx for the debridement (removal of dead or infected skin tissue for... 
Via Benzinga
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis... 
Via Benzinga
Earnings Scheduled For November 16, 2021
Companies Reporting Before The Bell • Ozon Holdings (NASDAQ:OZON) is expected to report quarterly loss at $0.90 per share on revenue of $602.00 million. • Sea (... 
Via Benzinga
Earnings Preview For MediWound
MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2021-11-16. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
MediWound's Earnings: A Preview
On Tuesday, August 10, MediWound (NASDAQ:MDWD) will release its latest earnings report. Benzinga's outlook for MediWound is included in the following report. Net Income, Earnings... 
Via Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer
MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC). In parallel, an investigator-initiated... 
Via Benzinga
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares rose 78.2% to $3.67 in pre-market trading after dropping more than 16% on Tuesday. Chembio’s filing recently showed... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
MediWound's NexoBrid Shows Significant Beneficial Impact On Pediatric Burn Patients
MediWound Ltd (NASDAQ: MDWD) has announced topline results from Phase 3 pediatric study with NexoBrid to treat severe thermal burns. The 145-subject study... 
Via Benzinga
20 Stocks Moving in Thursday's Pre-Market Session
Gainers Alterity Therapeutics Ltd (NASDAQ: ATHE) shares rose 64% to $2.14 in pre-market trading. Alterity Therapeutics recently said it received EU regulatory guidance for ATH434... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers BSQUARE Corporation (NASDAQ: BSQR) shares jumped 206.9% to close at $8.04 on Tuesday on abnormally-high volume possibly amid increased attention from retail investors.... 
Via Benzinga
Mid-Afternoon Market Update: US Stocks Mostly Flat; DiaMedica Therapeutics Shares Plunge
Toward the end of trading Tuesday, the Dow traded up 0.04% to 34,295.41 while the NASDAQ rose 0.13% to 14,518.98. The S&P traded flat at 4,290.65. The U.S. has the highest... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.